跳至主要内容
临床试验/NCT07252843
NCT07252843已完成不适用

Lymphedema Prediction Model in Breast Cancer After Axillary Lymph Node Dissection: A Study of Clinicopathological Factors, Receptor Expression (VEGFR3, TGFBR2), and Genetic Predisposition (GJA4, MET, GATA2)

Dharmais National Cancer Center Hospital1 个研究点 分布在 1 个国家目标入组 133 人开始时间: 2022年10月11日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
133
试验地点
1
主要终点
Occurrence of Arm Lymphedema

研究概览

简要总结

The goal of this observational ambidirectional cohort study is to develop a prediction model to identify the risk of lymphedema after axillary lymph node dissection (ALND) in patients with breast cancer. The main questions it aims to answer are:

  • Can clinicopathological factors predict the development of lymphedema?
  • Do protein expression profiles and genetic mutations increase susceptibility to lymphedema?

Participants will:

  • Undergo clinical evaluation and indocyanine green (ICG) lymphography to diagnose lymphedema.
  • Provide lymphatic tissue and blood samples during ALND surgery for immunohistochemical protein analysis and gene mutation assessment.
  • Be followed over time to monitor the onset and progression of lymphedema.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Histopathologically confirmed breast cancer
  • Undergoing axillary lymph node dissection (ALND)
  • Able to undergo indocyanine green (ICG) lymphography examination

排除标准

  • Clinical signs of lymphedema prior to surgery, confirmed by clinical assessment and/or ICG lymphography
  • History of iodine allergy, asthma, impaired renal function, pregnancy, or breastfeeding
  • Incomplete clinical or laboratory data required for analysis

结局指标

主要结局

Occurrence of Arm Lymphedema

时间窗: Up to 24 months post-axillary lymph node dissection

Development of lymphedema identified through clinical signs and symptoms, confirmed using indocyanine green (ICG) lymphography. The presence or absence of lymphedema will be recorded during follow-up assessments.

次要结局

未报告次要终点

研究者

发起方
Dharmais National Cancer Center Hospital
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Rizky Ifandriani Putri

MD

Dharmais National Cancer Center Hospital

研究点 (1)

Loading locations...

相似试验